Biotricity Inc.
- BTCY · OTC
- Surgical & Medical Instruments & Apparatus
- Redwood City, CA
- 46 employees
- CIK 0001630113
Updated from SEC filings through
Top things to know
Revenue, FY2026$16.0M+16.0% vs FY2025Operating margin10.6%Operating income $1.7MEmployees46As of March 31, 2026Next earningsNovember 14, 2026AnnouncedLatest 8-KDeparture or appointment of directors or officers; compensationFiled September 28, 2026Leadership changeItem 5.02 filedSeptember 28, 2026, last 90 days
Executives
- Waqaas Al-Siddiq President, Chief Executive Officer and Chairman of the Board of Directors 10-K, 2026-07-14
- John Ayanoglou Chief Financial Officer 10-K, 2026-07-14
Biotricity Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Redwood City, CA. It trades as BTCY on OTC. Revenue was $16.0M in the fiscal year ending March 31, 2026, +16.0% from the year before. It reported about 46 employees. Waqaas Al-Siddiq is President, Chief Executive Officer and Chairman of the Board of Directors.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $16.0M 10-K, 2026-07-14 | $13.8M 10-K, 2026-07-14 | $12.1M 10-K/A, 2025-07-18 | $9.6M 10-K, 2024-06-27 | $7.7M 10-K, 2023-06-29 |
| Operating income | $1.7M 10-K, 2026-07-14 | -$2.4M 10-K, 2026-07-14 | -$8.8M 10-K/A, 2025-07-18 | -$15.4M 10-K, 2024-06-27 | -$16.7M 10-K, 2023-06-29 |
| SG&A | $8.5M 10-K, 2026-07-14 | $10.9M 10-K, 2026-07-14 | $14.6M 10-K/A, 2025-07-18 | $17.6M 10-K, 2024-06-27 | $18.6M 10-K, 2023-06-29 |
| Net income | -$2.4M 10-K, 2026-07-14 | -$8.4M 10-K, 2026-07-14 | -$14.1M 10-K/A, 2025-07-18 | -$18.7M 10-K, 2024-06-27 | -$29.1M 10-K, 2023-06-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Waqaas Al-Siddiq | President, Chief Executive Officer and Chairman of the Board of Directors | 10-K, 2026-07-14 |
| John Ayanoglou | Chief Financial Officer | 10-K, 2026-07-14 |
| David A. Rosa | Director (Independent) | 10-K, 2026-07-14 |
| Jainal Bhuiyan | Director | 10-K, 2026-07-14 |
| Ron McClurg | Director (Independent) | 10-K, 2026-07-14 |
| Ronald McClurg | Director | 10-K, 2026-07-14 |
What Biotricity Inc. does
Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established.
Shares and governance
| Shares outstanding | 19.9 million (as of August 19, 2026) | 10-Q, August 19, 2026 |
|---|---|---|
| Public float | $13.5M (as of September 30, 2025) | 10-K, July 14, 2026 |
| Latest proxy statement | Meeting August 2, 2024 (filed August 5, 2024) | DEF 14A, August 5, 2024 |
| Auditor | SRCO Professional Corporation (Richmond Hill, Ontario, Canada) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-09-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-01
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-02-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-02-24
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2024-11-20
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2024-08-16
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2024-08-07
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2024-08-01
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2024-07-16
- Item 3.02 Unregistered sales of equity securities
- Item 8.01 Other events
Frequently asked questions about Biotricity Inc.
- What does Biotricity Inc. do?
- In its own words, from Item 1 of its 10-K: "Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established."
- What is Biotricity Inc.'s revenue?
- $16.0M for the fiscal year ending March 31, 2026, from its 10-K filed July 14, 2026.
- Is Biotricity Inc. profitable?
- Biotricity Inc. reported net income of -$2.4M for the fiscal year ending March 31, 2026.
- How many employees does Biotricity Inc. have?
- About 46 as of March 31, 2026, as stated in its annual report.
- Who is the CEO of Biotricity Inc.?
- Waqaas Al-Siddiq, President, Chief Executive Officer and Chairman of the Board of Directors, as named in a 10-K filed July 14, 2026.
- Who is the CFO of Biotricity Inc.?
- John Ayanoglou, Chief Financial Officer, as named in a 10-K filed July 14, 2026.
- Where is Biotricity Inc. headquartered?
- Redwood City, CA.
- What is Biotricity Inc.'s stock ticker?
- BTCY on OTC.
- What industry is Biotricity Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Biotricity Inc.'s website?
- biotricity.com.
- When does Biotricity Inc. report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Biotricity Inc. a public company?
- Yes. Biotricity Inc. files with the SEC under CIK 0001630113 and trades as BTCY.
- Who audits Biotricity Inc.?
- SRCO Professional Corporation, Richmond Hill, Ontario, Canada, as named in its latest annual report (10-K).
- How many shares of Biotricity Inc. are outstanding?
- 19.9 million shares as of August 19, 2026, from its 10-Q filed August 19, 2026.
- What is Biotricity Inc.'s public float?
- $13.5M as of September 30, 2025, as reported on the cover of its 10-K filed July 14, 2026.
- When is Biotricity Inc.'s annual shareholder meeting?
- August 2, 2024, per its proxy statement (DEF 14A) filed August 5, 2024.